Vaccines for the twenty-first century society
Open accessAbstract
Vaccines have been one of the major revolutions in the history of mankind and, during the twentieth century, they eliminated most of the childhood diseases that used to cause millions of deaths. In the twenty-first century, vaccines will also play a major part in safeguarding people's health. Supported by the innovations derived from new technologies, vaccines will address the new needs of a twenty-first century society characterized by increased life expectancy, emerging infections and poverty in low-income countries.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
New technologies will be required to address changing vaccine needs.
“However, with increasing life expectancy in high-income countries and newly emerging infections and poverty in low-income countries, new technologies will be required to address changing vaccine needs (1).”
From Nonviral delivery of self-amplifying RNA vaccines (2012) · cites this paper as [1]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Broken Limits to Life Expectancy
Oeppen, J., & Vaupel, J. W. (2002) · Science · doi:10.1126/science.1069675 · Cited by 2,819 · see citing works
The challenge of emerging and re-emerging infectious diseases
Morens, D. M., Folkers, G. K., & Fauci, A. S. (2004) · Nature · doi:10.1038/nature02759 · Cited by 2,107 · see citing works
Effectiveness of maternal influenza immunization in mothers and infants
Zaman, K., Roy, E., Arifeen, S. E., Rahman, M., Raqib, R., Wilson, E., Omer, S. B., Shahid, N. S., Breiman, R. F., & Steinhoff, M. C. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0708630 · Cited by 1,227 · see citing works
First Results of Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Children
The RTS, S. C. T. P. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102287 · Cited by 896 · see citing works
Steinhagen, F., Kinjo, T., Bode, C., & Klinman, D. M. (2010) · Vaccine · doi:10.1016/j.vaccine.2010.08.002 · Cited by 505 · see citing works
Infection, inflammation, height, and longevity
Crimmins, E. M., & Finch, C. E. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501470103 · Cited by 468 · see citing works
A systematic look at an old problem
Kirkwood, T. B. L. (2008) · Nature · doi:10.1038/451644a · Cited by 365 · see citing works
Emerging infections: a perpetual challenge
Morens, D. M., Folkers, G. K., & Fauci, A. S. (2008) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(08)70256-1 · Cited by 313 · see citing works
Roper, M. H., Vandelaer, J., & Gasse, F. L. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61261-6 · Cited by 311 · see citing works
Galli, G., Hancock, K., Höschler, K., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903181106 · Cited by 265 · see citing works
Is the development of a new tuberculosis vaccine possible?
Kaufmann, S. H. E. (2000) · Nature Medicine · doi:10.1038/79631 · Cited by 225 · see citing works
The Challenges of Vaccine Responses in Early Life: Selected Examples
Siegrist, C. A. (2007) · Journal of Comparative Pathology · doi:10.1016/j.jcpa.2007.04.004 · Cited by 204 · see citing works
Immunogenicity and Safety of a Meningococcal A Conjugate Vaccine in Africans
Sow, S. O., Okoko, B. J., Diallo, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1003812 · Cited by 178 · see citing works
Meningococcal C conjugate vaccine: the experience in England and Wales
Campbell, H., Borrow, R., Salisbury, D., & Miller, E. (2009) · Vaccine · doi:10.1016/j.vaccine.2009.04.067 · Cited by 168 · see citing works
The Intangible Value of Vaccination
Rappuoli, R., Miller, H. I., & Falkow, S. (2002) · Science · doi:10.1126/science.1075173 · Cited by 163 · see citing works
Self-citationMF59 adjuvant: the best insurance against influenza strain diversity
O’Hagan, D. T., Rappuoli, R., Gregorio, E. D., Tsai, T. F., & Giudice, G. D. (2011) · Expert Review of Vaccines · doi:10.1586/erv.11.23 · Cited by 150 · see citing works
Self-citationRomanowski, B. (2011) · Human Vaccines · doi:10.4161/hv.7.2.13690 · Cited by 125 · see citing works
Recommended Immunization Schedules for Persons Aged 0-18 Years - United States, 2007
(2007) · PsycEXTRA Dataset · doi:10.1037/e566752007-005 · Cited by 84 · see citing works
Vaccinate for the next H2N2 pandemic now
Nabel, G. J., Wei, C., & Ledgerwood, J. E. (2011) · Nature · doi:10.1038/471157a · Cited by 67 · see citing works
An Ill Wind, Bringing Meningitis
Roberts, L. (2008) · Science · doi:10.1126/science.320.5884.1710 · Cited by 57 · see citing works
Cost‐Effectiveness of a Potential ProphylacticHelicobacter pyloriVaccine in the United States
Rupnow, M. F. T., Chang, A. H., Shachter, R. D., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/605845 · Cited by 49 · see citing works
The 2010 scientific strategic plan of the Global HIV Vaccine Enterprise
Enterprise, M. O. T., Berkley, S., Bertram, K., et al. (2010) · Nature Medicine · doi:10.1038/nm0910-981 · Cited by 48 · see citing works
Fragapane, E., Gasparini, R., Schioppa, F. S., et al. (2010) · Clinical and Vaccine Immunology · doi:10.1128/cvi.00461-09 · Cited by 34 · see citing works
Pineau, P., & Tiollais, P. (2009) · Pathologie Biologie · doi:10.1016/j.patbio.2009.03.004 · Cited by 14 · see citing works
Eisenstein, M. S. (2011) · Nature · doi:10.1038/471s8a · Cited by 5 · see citing works
Flagged first, then by citations
Research works printed but not linked: 2
- [7]Centers for Disease Control and Prevention. Notes from the Field: Pertussis --- California, January--June 2010. Morb. Mortal. Wkly Rep.59, 817 (2010).
- [21]HHS pandemic influenza implementation plan. Chapter 5: vaccines. United States Department of Human & Health Services [online] (2006).
Cited by
Sorted by citations
A guide to vaccinology: from basic principles to new developments
Pollard, A. J., & Bijker, E. M. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00479-7 · Cited by 1,593 · see citing works
Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines
Hassett, K. J., Benenato, K. E., Jacquinet, E., Lee, A., Woods, A., Yuzhakov, O., Himansu, S., Deterling, J., Geilich, B. M., Ketova, T., et al. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.01.013 · Cited by 927 · see citing works
Nonviral delivery of self-amplifying RNA vaccines
Geall, A. J., Verma, A., Otten, G. R., Shaw, C. A., Hekele, A., Banerjee, K., Cu, Y., Beard, C. W., Brito, L. A., Krucker, T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1209367109 · Cited by 675 · see citing works
Self-citationProof of principle for epitope-focused vaccine design
Correia, B. E., Bates, J. T., Loomis, R. J., Baneyx, G., Carrico, C., Jardine, J. G., Rupert, P., Correnti, C., Kalyuzhniy, O., Vittal, V., et al. (2014) · Nature · doi:10.1038/nature12966 · Cited by 555 · see citing works
Vaccination in the elderly: The challenge of immune changes with aging
Ciabattini, A., Nardini, C., Santoro, F., Garagnani, P., Franceschi, C., & Medaglini, D. (2018) · Seminars in Immunology · doi:10.1016/j.smim.2018.10.010 · Cited by 411 · see citing works
A Cationic Nanoemulsion for the Delivery of Next-generation RNA Vaccines
Brito, L. A., Chan, M., Shaw, C. A., Hekele, A., Carsillo, T., Schaefer, M., Archer, J., Seubert, A., Otten, G. R., Beard, C. W., et al. (2014) · Molecular Therapy · doi:10.1038/mt.2014.133 · Cited by 338 · see citing works
Self-citationNabel, G. J. (2013) · New England Journal of Medicine · doi:10.1056/nejmra1204186 · Cited by 271 · see citing works
A novel, disruptive vaccination technology: Self-adjuvanted RNActive <sup>®</sup> vaccines
Kallen, K.-J., Heidenreich, R., Schnee, M., Petsch, B., Schlake, T., Thess, A., Baumhof, P., Scheel, B., Koch, S. D., & Fotin-Mleczek, M. (2013) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.25181 · Cited by 223 · see citing works
Immunization: vital progress, unfinished agenda
Piot, P., Larson, H. J., O’Brien, K. L., N’kengasong, J., Ng, E., Sow, S., & Kampmann, B. (2019) · Nature · doi:10.1038/s41586-019-1656-7 · Cited by 206 · see citing works
Structural vaccinology starts to deliver
Dormitzer, P. R., Grandi, G., & Rappuoli, R. (2012) · Nature Reviews Microbiology · doi:10.1038/nrmicro2893 · Cited by 143 · see citing works
Self-citationImmunosenescence and vaccine failure in the elderly: strategies for improving response
Boraschi, D., & Italiani, P. (2014) · Immunology Letters · doi:10.1016/j.imlet.2014.06.006 · Cited by 86 · see citing works
- Authors
- Rappuoli, R., Mandl, C. W., Black, S., & De Gregorio, E.
- Affiliations
- Novartis (Italy) (IT)
- Cincinnati Children's Hospital Medical Center (US)
- Corresponding author
- Rappuoli, Rino
- Venue
- Nature Reviews Immunology
- Published
- 2011-11-04
- Volume
- 11
- Issue
- 12
- Pages
- 865-872
- ISSN
- 1474-1733 (ISSN-L)
- 1474-1741
- PMC
- PMC7098427
- OpenAlex
- W1976948056
- Cited by
- 388
- References
- 25
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 16 · 2023: 24 · 2022: 30 · 2021: 24 · 2020: 27 · 2019: 32 · 2018: 20 · 2017: 27 · 2016: 32 · 2015: 36 · 2014: 35 · 2013: 32 · 2012: 26
- FWCI
- 2.67
- Type
- journal article
- Language
- en
- Update notices
- erratum (2012-01-30)
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Immunology (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- vaccines, vaccine development, childhood immunization, emerging infectious diseases, low-income countries, poverty, life expectancy
- MeSH terms
- Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Child, Child, Preschool, Developing Countries, Female, Forecasting, Humans, Infant, Infant, Newborn, Life Expectancy, Male, Middle Aged, Poverty, Pregnancy, Vaccination, Vaccines, Infection Control, Immunization Programs, Communicable Diseases, Emerging, Vulnerable Populations, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
